InnoCare Pharma saw the highest growth of 0.99% in patent filings in April and 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of InnoCare Pharma‘s patent filings and grants. Buy the databook here.
InnoCare Pharma has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with three publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 60% of filings. The World Intellectual Property Organization(WIPO), China(CN), Denmark(DK), and European Patent Office(EPO) patent Office are among the top ten patent offices where InnoCare Pharma is filings its patents. Among the top granted patent authorities, InnoCare Pharma has 20% of its grants in European Patent Office(EPO) and 20% in Finland(FI).
Roche could be the strongest competitor for InnoCare Pharma
Patents related to cell & gene therapy lead InnoCare Pharma's portfolio
InnoCare Pharma has the highest number of patents in cell & gene therapy. For cell & gene therapy, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Multiple sclerosis related patents lead InnoCare Pharma portfolio
InnoCare Pharma has highest number of patents in multiple sclerosis.
For comprehensive analysis of InnoCare Pharma's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.